• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by NeuroOne Medical Technologies Corporation

    12/19/25 4:30:53 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care
    Get the next $NMTC alert in real time by email
    S-8 1 ea0270112-s8_neuroone.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on December 19, 2025

    Registration No. 333-               

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    NeuroOne Medical Technologies Corporation

    (Exact name of registrant as specified in its charter)

     

    Delaware   27-0863354
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification Number.)

     

    7599 Anagram Dr.,
    Eden Prairie, MN
      55344
    (Address of principal executive offices)   (Zip code)

     

    NeuroOne Medical Technologies Corporation 2021 Inducement Plan

    (Full title of the plan)

     

    David Rosa

    President and Chief Executive Officer

    NeuroOne Medical Technologies Corporation

    7599 Anagram Dr.,
    Eden Prairie, MN 55344

    952-426-1383

    (Name, address, and telephone number, including area code, of agent for service)

     

    Copy to:

     

    Phillip D. Torrence, Esq.

    Jeffrey Kuras, Esq.

    Honigman LLP

    650 Trade Centre Way, Suite 200

    Kalamazoo, Michigan 49002-0402

    (269) 337-7700

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Smaller reporting company ☒
          Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed by NeuroOne Medical Technologies Corporation, a Delaware corporation. (the “Company” or “Registrant”) for the purpose of registering an additional 575,000 shares of the Registrant’s common stock, $0.001 par value (the “Common Stock”) issuable pursuant to the Registrant’s 2021 Inducement Plan (the “Inducement Plan”).

     

    Pursuant to General Instruction E to Form S-8, this Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Company on Form S-8 relating to the Inducement Plan is effective, and the Company’s Registration Statements on Form S-8 previously filed with the Securities and Exchange Commission (the “Commission”) on December 15, 2023 (File No. 333-276079) and November 23, 2021 (File No. 333-261302) registering shares of Common Stock issuable under the Inducement Plan are incorporated by reference in this Registration Statement.

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference.

     

    The following documents filed with the Commission by the Registrant are hereby incorporated by reference in this Registration Statement:

     

    (a)our Annual Report on Form 10-K for the year ended September 30, 2025 filed with the Commission on December 17, 2025;

     

    (b)our Current Reports on Form 8-K filed with the Commission on October 6, 2025 and November 5, 2025; and

     

    (c)the description of our Common Stock in our registration statement on Form 8-A filed with the SEC on May 25, 2021 and as amended by any subsequent amendment or report filed for the purpose of updating such description.

     

    In addition, all documents the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, after the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities covered hereby then remaining unsold are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents. Notwithstanding anything herein, the Registrant is not incorporating by reference any information furnished under Item 2.02 or Item 7.01 of any Current Report on Form 8-K, unless, and to the extent, specified in any such Current Report on Form 8-K.

     

    Any statement herein or contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any subsequently filed document, which also is or is deemed to be incorporated by reference herein, modifies or supersedes such prior statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.

     

    II-1

     

     

    Item 8. Exhibits.

     

    EXHIBIT INDEX

     

    The following exhibits are filed as part of this Registration Statement.

     

    INDEX TO EXHIBITS

     

    Exhibit
    Number
      Description
    4.1   Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.4 on the Registrant’s Current Report on Form 8-K filed on June 29, 2017)
         
    4.2   Certificate of Amendment to Amended and Restated Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant’s Current Report on Form 8-K filed on March 31, 2021)
         
    4.3   Amended and Restated Bylaws of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant’s Current Report on Form 8-K filed on June 21, 2024)
         
    4.4   NeuroOne Medical Technologies Corporation 2021 Inducement Plan (incorporated by reference to Exhibit 10.1 on the Registrant’s Current Report on Form 8-K filed on October 4, 2021)
         
    4.5   First Amendment to NeuroOne Medical Technologies Corporation 2021 Inducement Plan (incorporated by reference to Exhibit 10.2 on the Registrant’s Current Report on Form 8-K filed on November 14, 2023)
         
    4.6   Second Amendment to NeuroOne Medical Technologies Corporation 2021 Inducement Plan (incorporated by reference to Exhibit 10.1 on the Registrant’s Quarterly Report on Form 10-Q filed on August 14, 2025)
         
    5.1   Opinion of Honigman LLP
         
    23.1   Consent of Baker Tilly US, LLP
         
    23.2   Consent of Honigman LLP (included in its opinion filed as Exhibit 5.1 to this Registration Statement)
         
    24.1   Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement)
         
    107   Filing Fee Table

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Eden Prairie, State of Minnesota, on December 19, 2025.

     

      NeuroOne Medical Technologies Corporation
       
      By: /s/ David Rosa
        David Rosa
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints David Rosa and Ronald McClurg, or either of them, as his or her true and lawful attorneys-in-fact and agents, with the full power of substitution and resubstitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ David Rosa   President and Chief Executive Officer   December 19, 2025
    David Rosa   (Principal Executive Officer) and a Director    
             
    /s/ Ronald McClurg   Chief Financial Officer (Principal Financial Officer and   December 19, 2025
    Ronald McClurg   Principal Accounting Officer)    
             
    /s/ Paul Buckman   Director   December 19, 2025
    Paul Buckman        
             
    /s/ Jeffrey Mathiesen   Director   December 19, 2025
    Jeffrey Mathiesen        
             
    /s/ Edward Andrle   Director   December 19, 2025
    Edward Andrle        
             
    /s/ Jason Mills   Director   December 19, 2025
    Jason Mills        

     

    II-3

     

     

    Get the next $NMTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NMTC

    DatePrice TargetRatingAnalyst
    5/5/2025$1.45Buy
    Ladenburg Thalmann
    3/29/2022$6.00 → $2.00Buy → Hold
    Craig Hallum
    12/3/2021$5.75Buy
    Alliance Global Partners
    11/15/2021$6.00Buy
    Craig-Hallum
    More analyst ratings

    $NMTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Mertens Steve covered exercise/tax liability with 7,376 shares, decreasing direct ownership by 5% to 153,047 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    2/20/26 2:27:42 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Business Development Director Christianson Mark covered exercise/tax liability with 1,812 shares, decreasing direct ownership by 0.79% to 228,920 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    2/20/26 2:20:36 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    CEO and President Rosa David A covered exercise/tax liability with 71,325 shares, decreasing direct ownership by 6% to 1,082,590 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    2/20/26 2:15:19 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $NMTC
    SEC Filings

    View All

    NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)

    2/17/26 8:00:51 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by NeuroOne Medical Technologies Corporation

    10-Q - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)

    2/17/26 7:01:02 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form 10-K/A filed by NeuroOne Medical Technologies Corporation

    10-K/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)

    1/23/26 4:30:28 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $NMTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025

    EDEN PRAIRIE, Minn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will be participating in the Sidoti & Co. Virtual Small-Cap Conference being held September 17-18, 2025. Dave Rosa, President and Chief Executive Officer, and Ron McClurg, Chief Financial Officer, are scheduled to present on September 17th at 12:15pm Eastern Time and will also be hosting one-on-one meetings with institutional investors throughout the event. Sidoti Small-Cap Virtual ConferenceDate: Wednesday, Sept

    9/8/25 4:05:00 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

    FDA Clearance Further Validates Technology Platform and Offers Alternatives to Pharmaceutical and Invasive Surgical Treatments EDEN PRAIRIE, Minn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has received U.S. Food and Drug Administration ("FDA") clearance to market its OneRF® Trigeminal Nerve Ablation System for use in procedures to create radiofrequency lesions for the treatment of pain, or for lesioning nerve tissue for functional neurosurgical procedures. As previously annou

    8/18/25 8:30:00 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%

    Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the third quarter of fiscal year 2025 ended June 30, 2025. Recent Company Highlights Product revenue increased 105% to $1.7 million in the third quarter of fiscal year 2025, compared to $0.8 million in the third quarter of fiscal year 2024.Product gross margin expanded significantly to 53.9% in the third

    8/14/25 7:30:00 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $NMTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $NMTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chief Financial Officer Mcclurg Ronald W. bought $100,000 worth of shares (200,000 units at $0.50), increasing direct ownership by 82% to 444,117 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    4/7/25 4:47:21 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    CEO and President Rosa David A bought $50,000 worth of shares (100,000 units at $0.50), increasing direct ownership by 9% to 1,161,289 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    4/7/25 4:38:47 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Volker Christopher bought $105,000 worth of shares (75,000 units at $1.40) (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    12/26/23 4:08:51 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Ladenburg Thalmann initiated coverage on Numerical Tech with a new price target

    Ladenburg Thalmann initiated coverage of Numerical Tech with a rating of Buy and set a new price target of $1.45

    5/5/25 8:32:14 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Numerical Tech downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Numerical Tech from Buy to Hold and set a new price target of $2.00 from $6.00 previously

    3/29/22 8:37:16 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Alliance Global Partners initiated coverage on NeuroOne Medical Tech with a new price target

    Alliance Global Partners initiated coverage of NeuroOne Medical Tech with a rating of Buy and set a new price target of $5.75

    12/3/21 9:56:11 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $NMTC
    Leadership Updates

    Live Leadership Updates

    View All

    NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

    EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has strengthened its management team with the appointment of Emily Johns as General Counsel and Corporate Secretary. Dave Rosa, President and CEO of NeuroOne said, "We are excited to welcome Emily to NeuroOne especially after working with her for almost a decade. Her legal acumen and experience navigating dynamic, fast-growing organizations will be invaluable as we continue to scale our business.

    6/3/25 8:30:00 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor

    Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies EDEN PRAIRIE, Minn., May 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has appointed Parag G. Patil, M.D., Ph.D., as Chief Medical Advisor (CMA), after serving on the company's Scientific Advisory Board since 2018. Dr. Parag G. Patil is a neurosurgeon-engineer with 20 years' experience serving patients and advancing innovative therapies to alleviate neurol

    5/12/25 8:30:00 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Volker strengthens existing management team in areas of commercialization, business development, and reimbursement EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has appointed medtech executive Christopher R. Volker as Chief Operating Officer. Mr. Volker joins NeuroOne from Abbott Laboratories which acquired Cardiovascular Systems, Inc. in April 2023. Mr. Volker held the role of Vice President and General Manager of International at

    11/14/23 5:15:00 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $NMTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

    SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

    11/26/24 8:42:10 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

    SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

    11/14/24 3:41:01 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by NeuroOne Medical Technologies Corporation

    SC 13G - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

    2/14/24 4:51:41 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $NMTC
    Financials

    Live finance-specific insights

    View All

    NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%

    Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the third quarter of fiscal year 2025 ended June 30, 2025. Recent Company Highlights Product revenue increased 105% to $1.7 million in the third quarter of fiscal year 2025, compared to $0.8 million in the third quarter of fiscal year 2024.Product gross margin expanded significantly to 53.9% in the third

    8/14/25 7:30:00 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update

    EDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal third quarter ended June 30, 2025, before market open on August 14, 2025. Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Thursday, August 14, 2025, to discuss the Company's third quarter fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use

    7/31/25 12:12:00 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time

    EDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal third quarter ended June 30, 2025, before market open on August 14, 2025. Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Thursday, May 14, 2025, to discuss the Company's third quarter fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the

    7/31/25 8:30:00 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care